Sodium glucose cotransporter 2 inhibitors possess the capability to improve glycemic status along with weight reduction in patients with type 2 diabetes with non‐alcoholic fatty liver disease. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.